In a variety of pathological conditions, including AD, cerebral amyloid angiopathy, and metabolic diseases such as type 2 diabetes and obesity, BACE1 expression and activity are increased and drive disease progression.3, 34, 39, 40. Here, BACE1 is linked to type 2 diabetes mellitus.